<html>
<head>
  <title>SARS-CoV-2 3C-like protease (a.k.a. NSP5, Mpro, main protease) (3CL) gene L167F literature reference collection</title>
  <link rel="stylesheet" href="constellations.css">
</head>
<body>
<h1><a href="front.html">SARS-CoV-2</a> <a href="3CL.html">3C-like protease (a.k.a. NSP5, Mpro, main protease) (3CL)</a> gene <span class="constellation">3CL:p.L167F</span> literature reference collection</h1>
<div class="effect_section"><h2 id="pharmaceutical_effectiveness">Pharmaceutical effectiveness</h2>
<ul class="lit_list">
<li class="lit_item"><span class="lit_summary"> P8 and p12 had dominant mutations in 3CLpro. Antiviral testing with p13 stock indicated strong resistance toALG-097161and cross-resistance to both nirmatrelvir and  PF-00835231. EC50 increased 63x for ALG-097161. EC50 increased 51x for Nirmatrelvir. EC50 increased 23x for PF-00835231. EC50 increased 2.1x for GS-441524. Tested    using FRET assay.<br/> (<a href="https://doi.org/10.1101/2022.06.07.495116" class="lit_link">Jochmans et al. (2022)</a>)</span></li>
</ul></div>
<div class="acknowledgement">Automatically generated using text2ui script and data from <a href="https://github.com/nodrogluap/pokay">Pokay</a></div>
</body>
</html>
